Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel peptidome for improving pre-eclampsia placental dysfunction

A technology for preeclampsia and dysfunction, applied in the field of medicine, can solve the problems of maternal-fetal toxicity and side effects, and achieve the effects of good stability, low molecular weight and good lipophilicity

Active Publication Date: 2019-10-08
NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to provide a novel polypeptide for improving placental dysfunction in preeclampsia, so as to solve the problem that most drugs for improving placental dysfunction in preeclampsia have certain toxic and side effects on the mother and fetus.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel peptidome for improving pre-eclampsia placental dysfunction
  • Novel peptidome for improving pre-eclampsia placental dysfunction
  • Novel peptidome for improving pre-eclampsia placental dysfunction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Further, the application of the polypeptide in a medicine or medicament for improving placental dysfunction of preeclampsia, wherein the polypeptide and the polypeptide composition can be made into any pharmaceutically acceptable dosage form.

[0026] The rats are bred in an environment with controlled light and humidity, eat freely and drink tap water freely. Under these conditions, they can adapt for a week. Fertile females and males are reared at a ratio of 1:1 overnight, and the plugs are picked in the morning, such as Existence is confirmed to have been pregnant, this day is GD 0. At the 14th day of pregnancy, pregnant mice were randomly assigned to three groups. The first group (Saline) (n=10): On the 14th day of pregnancy, each rat received normal saline (1mg / kg) through the tail vein; the second group (LPS): On the 14th day of pregnancy, LPS was injected through the tail vein (1μg / kg); The third group (LPS+Cys-peptide): At the 14th day of pregnancy, the rats were ...

Embodiment 2

[0033] Further, the application of polypeptides in reducing urine protein / creatinine levels in preeclampsia pregnant rats.

[0034] Sprague-Dawley (SD) rats (10-12 weeks, 280-350g) were purchased from the Experimental Animal Center of Nanjing Medical University. The rats are kept in an environment with controlled light and humidity, eat freely and drink tap water freely.

[0035] After one week of acclimatization, the fertile females and males were reared overnight at a ratio of 1:1, and the plugs were picked up in the morning. If they exist, they were confirmed to be pregnant. This day is GD 0. (Under standard laboratory conditions (temperature 23-26℃, relative humidity 50-60%, irradiation between 06:00am and 06:00pm), free access to pelleted food and water)

[0036] At the 14th day of pregnancy, pregnant rats were randomly assigned to three groups: Group 1 (Sal ine) (n=10): On day 14 of pregnancy, each rat received normal saline (1mg / kg) through the tail vein; Group 2 (PE ) Rats ...

Embodiment 3

[0041] Further, the application of the polypeptide in improving the utilization rate of the placenta of pregnant mice with preeclampsia.

[0042] Praague-Dawley (SD) rats (10-12 weeks, 280-350g) were purchased from the Experimental Animal Center of Nanjing Medical University. The rats are kept in an environment with controlled light and humidity, eat freely and drink tap water freely.

[0043] After one week of acclimatization, the fertile females and males were reared overnight at a ratio of 1:1, and the plugs were picked up in the morning. If they exist, they were confirmed to be pregnant. This day is GD 0. (Under standard laboratory conditions (temperature 23-26℃, relative humidity 50-60%, irradiation between 06:00am and 06:00pm), free access to pelleted food and water)

[0044] At the 14th day of pregnancy, pregnant rats were randomly assigned to three groups: Group 1 (Sal ine) (n=10): On day 14 of pregnancy, each rat received normal saline (1mg / kg) through the tail vein; Group ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a novel peptidome for improving pre-eclampsia placental dysfunction, and relates to the related field of medicine. The novel peptidome solves the problem that most drugs for improving the pre-eclampsia placental dysfunction in the prior art have certain toxic and side effects on a mother womb. The peptidome has a sequence of Ac-RFAACAA-COOH, the peptidome is applied to drugs or medicaments for improving the pre-eclampsia placental dysfunction, the peptidome is applied to reduction of the level of urinary proteins / creatinine in pre-eclampsia pregnant rats, the peptidomeis applied to increase of the placental utilization rate of the pre-eclampsia pregnant rats, and the peptidome is applied to inversion of TNF alpha inhibition to migration and invasion of trophoblast.

Description

Technical field [0001] The invention relates to the field of medicine, in particular to a novel polypeptide for improving placental dysfunction in preeclampsia. Background technique [0002] Pre-eclampsia (Pre-eclampsia, PE) is a unique disease during pregnancy, which can cause multiple organ dysfunction, cerebral edema, fetal growth restriction, etc., and is one of the diseases with the highest mortality of pregnant women and fetuses. According to statistics, about 49,000 pregnant women and 50,000 perinatal infants die from preeclampsia and its complications each year, accounting for 14% of all causes of maternal death; the incidence of PE in my country is as high as 3.91-5.57%, which seriously harms the mothers And fetal health. At present, except for a few drugs such as labetalol and nifedipine which are relatively safe, the others have toxic and side effects on the mother and the fetus. Today, when treatment measures are extremely lacking, the termination of pregnancy is stil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K7/06A61K38/08A61P15/00
CPCC07K7/06A61P15/00A61K38/00
Inventor 丁虹娟贾瑞喆崔县伟沈嵘凌钟慧季小红薛路
Owner NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com